Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Measure serum and cerebrospinal fluid Sema4A levels in female subjects with newly diagnosed and untreated relapsing multiple sclerosis, clinically stable relapsing multiple sclerosis receiving disease modifying therapy, relapsing multiple sclerosis receiving disease modifying therapy with breakthrough disease, or non-multiple sclerosis controls (patients without inflammatory central nervous system disease).
Epistemonikos ID: 21e30459d000dbac566ee9fe1f0a4ea0be014208
First added on: May 09, 2024